基线β-catenin、程序性死亡配体1表达及肿瘤浸润淋巴细胞预测BRAF抑制剂治疗的黑色素瘤患者的缓解与不良预后
研究分析64例接受BRAF抑制剂单药或BRAF联合MEK抑制剂治疗的转移性黑色素瘤患者治疗前肿瘤样本,采用免疫组化检测β-catenin、PD-L1、CD8、CD103及FOXP3表达并与临床结局关联。多因素分析显示PD-L1<5%和存在CD8+ T细胞与MAPK抑制剂单药治疗更高的缓解概率显著相关;CD8+ T细胞高密度且β-catenin<10%的患者无进展生存和总生存更长。
要点
- PD-L1<5%与MAPK抑制剂单药治疗缓解概率升高显著相关(OR 0.12)。
- 存在CD8+ T细胞与MAPK抑制剂单药治疗缓解概率升高显著相关(OR 18.27)。
- CD8+ T细胞高密度且β-catenin<10%者PFS和OS更长。
核心结论
- 在MAPK抑制剂单药治疗背景下,肿瘤微环境中的免疫细胞亚群和基因特征可预测转移性黑色素瘤患者的预后。
研究设计与样本
- 研究纳入64例转移性黑色素瘤患者治疗前福尔马林固定石蜡包埋肿瘤样本,其中接受BRAF抑制剂治疗39例、BRAF联合MEK抑制剂治疗25例。
- 采用免疫组化评估β-catenin、PD-L1、CD8、CD103和FOXP3表达,并与临床结局进行关联分析。
- 对51例患者进行Wnt/β-catenin通路和免疫反应相关mRNA转录本的定量评估。
主要发现
- 肿瘤β-catenin表达与肿瘤微环境中CD8、CD103或FOXP3阳性水平呈负相关。
- 多因素分析显示,PD-L1<5%(OR 0.12,95%CI 0.03-0.53,p=0.005)和存在CD8+ T细胞(OR 18.27,95%CI 2.54-131.52,p=0.004)与MAPK抑制剂单药治疗更高的缓解概率显著相关。
- 缓解患者中适应性免疫和抗原呈递相关的mRNA转录本表达显著增加。
- 多因素分析显示,CD8+ T细胞高密度且β-catenin<10%的患者较无CD8+ T细胞浸润且β-catenin≥10%的患者,无进展生存期(HR=0.25,95%CI 0.10-0.61,p=0.002)和总生存期(HR=0.24,95%CI 0.09-0.67,p=0.006)更长。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The activation of oncogenic Wnt/β-catenin pathway in melanoma contributes to a lack of T-cell infiltration. Whether baseline β-catenin expression in the context of tumour-infiltrating lymphocytes (TILs) and programmed death ligand-1 (PD-L1) overexpression correlates with prognosis of metastatic melanoma patients (MMPs) treated with mitogen-activated protein kinase, MAPK inhibitor (MAPKi) monotherapy, however, has not been fully clarified. PATIENTS AND METHODS: Sixty-four pre-treatment formalin-fixed and paraffin embedded melanoma samples from MMP treated with a BRAF inhibitor (n = 39) or BRAF and MEK inhibitors (n = 25) were assessed for presence of β-catenin, PD-L1, cluster of differentiation (CD)8, CD103 and forkhead box protein P3 (FOXP3) expression by immunohistochemistry, and results were correlated with clinical outcome. Quantitative assessment of mRNA transcripts associated with Wnt/β-catenin pathway and immune response was performed in 51 patients. RESULTS: We found an inverse correlation between tumoural β-catenin expression and the level of CD8, CD103 or forkhead box protein P3 (FOXP3) positivity in the tumour microenvironment (TME). By multivariate analysis, PD-L1 <5% (odds ratio, OR 0.12, 95% confidence interval, CI 0.03-0.53, p = 0.005) and the presence of CD8+ T cells (OR 18.27, 95%CI 2.54-131.52, p = 0.004) were significantly associated with a higher probability of response to MAPKi monotherapy. Responding patients showed a significantly increased expression of mRNA transcripts associated with adaptive immunity and antigen presentation. By multivariate analysis, progression-free survival (PFS) (hazards ratio (HR) = 0.25 95%CI 0.10-0.61, p = 0.002) and overall survival (OS) (HR = 0.24 95%CI 0.09-0.67, p = 0.006) were longer in patients with high density of CD8+ T cells and β-catenin <10% than those without CD8+ T cells infiltration and β-catenin ≥10%. CONCLUSION: Our findings provide evidence that in the context of MAPKi monotherapy, immune subsets in the (TME) and gene signature predict prognosis in MMPs.
引用
- Massi D, Romano E, Rulli E, et al. Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients. Eur J Cancer. 2017. PMID: 28412591. doi:10.1016/j.ejca.2017.03.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。